Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL628 in early Alzheimer's disease
NL-OMON58797Phase 1Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of DNL628 in Alzheimer's disease (AD), sponsored by Denali Therapeutics Inc. Started Apr 2026; status: recruiting.
02
Drugs
DNL628
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON58797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58797.